Cubosomes: A Novel Nanotechnology-Based Drug Delivery System for Osteoarthritis Treatment

Osteoarthritis (OA) is a chronic joint disorder characterized by cartilage degradation, inflammation, and pain, leading to impaired mobility. Conventional treatments, such as NSAIDs, corticosteroids, and hyaluronic acid injections, often provide only temporary relief and are associated with systemic side effects. Cubosomes, self-assembled nanostructured lipid carriers, have emerged as a promising drug delivery system for OA treatment due to their biocompatibility, sustained drug release, and ability to encapsulate both hydrophilic and hydrophobic drugs. They offer targeted delivery of anti-inflammatory agents, regenerative molecules, and analgesics, reducing systemic exposure while enhancing therapeutic efficacy. Additionally, cubosomes can be engineered for cartilage regeneration and gene therapy applications to slow OA progression. Despite challenges such as stability and large-scale production, ongoing research aims to optimize cubosome-based formulations for intra-articular drug delivery. This nanotechnology-driven approach holds significant potential for improving OA management, reducing side effects, and enhancing long-term joint health.